SLAMF7 and Miyoshi myopathy: Compared with CD38 and SLAMF7, B cell maturation antigen (BCMA) demonstrates highly restricted expression on PCs but no other tissues, is, therefore, an excellent target for immunotherapy in MM (41, 42).